Melanoma Research最新文献_第2页

High-resolution RNA-sequencing reveals TRIM33 :: CSDE1 gene fusion in metastasizing vulvar melanoma. 高分辨率 RNA 测序发现转移性外阴黑色素瘤中存在 TRIM33::CSDE1 基因融合。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-01 Epub Date: 2024-09-18 DOI: 10.1097/CMR.0000000000001005

Magdalena Stawiarz, Mai P Hoang, Artur Kowalik

引用次数: 0

Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials. 塔利莫gene laherparepvec和粒细胞-巨噬细胞集落刺激因子治疗转移性黑色素瘤的有效性和安全性：随机对照试验的系统评价和网络荟萃分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-01 Epub Date: 2024-12-24 DOI: 10.1097/CMR.0000000000001010

Yu-Chun Shen, Ya-Li Huang, Yi-No Kang, Wen-Kuan Chiu, Khanh Dinh Hoang, Hsian-Jenn Wang, Chiehfeng Chen

{"title":"Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials.","authors":"Yu-Chun Shen, Ya-Li Huang, Yi-No Kang, Wen-Kuan Chiu, Khanh Dinh Hoang, Hsian-Jenn Wang, Chiehfeng Chen","doi":"10.1097/CMR.0000000000001010","DOIUrl":"10.1097/CMR.0000000000001010","url":null,"abstract":"Melanoma is an aggressive tumor that is challenging to treat. Talimogene laherparepvec (T-VEC), the first oncolytic virus treatment approved by the US Food and Drug Administration to treat unresectable melanoma, was recently used in recurrent tumors after initial surgery. Our network meta-analysis aimed to compare T-VEC treatment of metastatic melanoma with treatment of granulocyte-macrophage colony-stimulating factor (GM-CSF) and control group. The protocol for this network meta-analysis was retrospectively registered with PROSPERO (CRD42022363321). Three databases, namely Embase, PubMed, and Cochrane Library, were searched until 10 June 2024. The search terms used were a combination of 'metastatic melanoma', 'melanoma', 'T-VEC', 'talimogene laherparepvec', and 'GM-CSF'. Seven studies, with 978 participants receiving T-VEC treatment, 649 participants receiving GM-CSF treatment, and 938 participants constituting the control group, were included in our meta-analysis. For 1-year overall survival (OS), the league table revealed significant differences between the control and T-VEC groups [0.90 (0.83, 0.99)]. The disease-free survival (DFS) over 2 years was also analyzed showing no difference between the groups in DFS in the league table. T-VEC may be a favorable treatment for metastatic melanoma owing to the notable increase in OS. Nevertheless, due to the side effects and limitations, the clinical benefits of T-VEC therapy in metastatic melanoma should be interpreted cautiously. This network meta-analysis demonstrates that T-VEC may be a favorable choice of treatment for metastatic melanoma.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"35 1","pages":"60-66"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study. 日本患者外阴和阴道恶性黑色素瘤的临床特征和免疫检查点抑制剂的作用：一项单中心、回顾性队列研究

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-01 Epub Date: 2024-12-03 DOI: 10.1097/CMR.0000000000001012

Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara

{"title":"Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.","authors":"Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara","doi":"10.1097/CMR.0000000000001012","DOIUrl":"10.1097/CMR.0000000000001012","url":null,"abstract":"Vulvar and vaginal melanomas (VVMs) are rare malignancies, but they are relatively more common among Asian women. This makes the collection of data on VVMs in this population crucial. Moreover, no cohort studies have examined and compared the effects of immune checkpoint inhibitors (ICIs) on VVM in Asian women. Therefore, we aimed to investigate the clinical characteristics of VVMs in Japanese women and the effects of ICI treatment. This single-center, retrospective cohort study included patients who were histologically diagnosed with VVM at our hospital between March 2005 and December 2023. The Kaplan-Meier analysis was used to compare the prognosis of vulvar melanoma (VuM) and vaginal melanoma (VaM) throughout entire treatments and compare the efficacies of ICIs and conventional chemotherapies in VVM. In total, 28 women with VuM ( n = 14) and VaM ( n = 14) were included. There were no significant differences in overall survival (OS) [median OS: not reached (95% confidence interval (CI), 13.2-NA) vs. 30.2 months (95% CI, 23.2-NA), log-rank test, P = 0.456] between the VuM and VaM groups. The progression-free survival (median progression-free survival: 14.7 vs. 5.2 months, P = 0.002) and OS (median OS: 33.8 vs. 7.2 months, P < 0.001) were significantly better for the ICI-treated group than for the conventional chemotherapy-treated group in VVM. The prognosis of patients with VVM improved significantly with the advent of ICI, demonstrating the importance of ICI in the treatment of VVM.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"67-74"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis. 接受PD-1/PD-L1阻断剂治疗的黑色素瘤患者基线中性粒细胞与淋巴细胞比率与预后的关系：系统综述和荟萃分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-01 Epub Date: 2024-10-08 DOI: 10.1097/CMR.0000000000001006

Michele Kreuz, Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Fernando Luiz Westphal Filho, Ana Laura Soares Silva, Francinny Alves Kelly

{"title":"Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis.","authors":"Michele Kreuz, Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Fernando Luiz Westphal Filho, Ana Laura Soares Silva, Francinny Alves Kelly","doi":"10.1097/CMR.0000000000001006","DOIUrl":"10.1097/CMR.0000000000001006","url":null,"abstract":"Immunotherapy treatments that target programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) have revolutionized the treatment of metastatic melanoma and currently represent the standard first-line treatment for this type of cancer. However, it is still not entirely clear which biomarkers are cost-effective, simple, and highly reliable. This systematic review and meta-analysis aims to analyze the predictive value of the baseline neutrophil-lymphocyte ratio (NLR) regarding disease progression and overall survival of patients with metastatic melanoma undergoing treatment with PD-1/PD-L1 blockade. PubMed, Scopus, and Web of Science were searched for studies comparing high versus low NLR. We performed the meta-analysis using RStudio v4.4.2 software. A total of 20 studies and 2691 patients were included, all with diagnoses of melanoma. The majority of the individuals were male 2278 (84, 65%). The median overall survival (OS) and progression-free survival (PFS) ranged from 5.0 to 44.4 and from 1.8 to 15.0 months, respectively. Compared with the high NLR ratio, the low exposure group achieved better rates of OS [hazard ratio (HR), 2.07; 95% CI, 1.73-2.48; P < 0.00001; I ² = 47%]. Regarding PFS, there was a statistically significant difference between groups with tendencies toward the low NLR exposure group (HR, 1.59; 95% CI, 1.39-1.81; P < 0.00001; I²=31%]. This systematic review and meta-analysis revealed significant lower OS in melanoma patients treated with PD-1/PD-L1 blockade who had elevated baseline NLR values. Furthermore, an increased PFS was observed in patients with a lower baseline NLR value. This study highlights NLR as an important prognostic biomarker for patients with metastatic melanoma who are candidates for treatment with PD-1 and PD-L1.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychosocial wellbeing in people with melanoma in-situ: a systematic review. 原位黑色素瘤患者的社会心理健康：系统综述。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-02-01 Epub Date: 2024-11-25 DOI: 10.1097/CMR.0000000000001007

Lejie Zheng, Alyssa Kathleen Susanto, H Peter Soyer, Monika Janda, Soraia de Camargo Catapan

{"title":"Psychosocial wellbeing in people with melanoma in-situ: a systematic review.","authors":"Lejie Zheng, Alyssa Kathleen Susanto, H Peter Soyer, Monika Janda, Soraia de Camargo Catapan","doi":"10.1097/CMR.0000000000001007","DOIUrl":"10.1097/CMR.0000000000001007","url":null,"abstract":"This systematic review aims to evaluate the prevalence of reductions in psychosocial wellbeing among patient with melanoma in situ (MIS). It also aims to identify factors associated with psychosocial reactions, the instruments used to measure psychosocial outcomes, and to evaluate existing intervention programs for supporting this population. Search strategies for different databases including PubMed, Embase, Scopus, PsycINFO, and Web of Science were designed and implemented. A total of 2378 records were identified, resulting in 22 included papers. Various aspects of psychosocial wellbeing were evaluated in the reviewed articles, with fear of cancer recurrence being the most frequently investigated among patients diagnosed with melanoma. Only 2 of the 22 studies reported data for MIS patients, indicating no significant difference in psychosocial welling between patients with MIS and those at higher stages. Regarding interventional support, there is a notable lack of interventions specifically addressing the psychosocial needs of MIS patients. Our findings highlight a significant research gap on psychosocial wellbeing following a MIS diagnosis and suggest a shortage of targeted psychosocial interventions for this growing patient population. The observed variability in measuring psychosocial aspects presents challenges in identifying the essential components of effective interventions. Future research should prioritize employing mixed methodologies and addressing the unique needs of MIS patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"11-23"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-01-29 DOI: 10.1097/CMR.0000000000001023

Colin D Angell, Steven H Sun, Gabriella Lapurga, Brooke Benner, Dionisia Quiroga, Himanshu Savardekar, Mallory J DiVincenzo, David Abood, Andrew Stiff, Megan Duggan, Demond Handley, Erin Nagle, J Harrison Howard, Hiral Shah, Kari L Kendra, William E Carson

{"title":"A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.","authors":"Colin D Angell, Steven H Sun, Gabriella Lapurga, Brooke Benner, Dionisia Quiroga, Himanshu Savardekar, Mallory J DiVincenzo, David Abood, Andrew Stiff, Megan Duggan, Demond Handley, Erin Nagle, J Harrison Howard, Hiral Shah, Kari L Kendra, William E Carson","doi":"10.1097/CMR.0000000000001023","DOIUrl":"10.1097/CMR.0000000000001023","url":null,"abstract":"Myeloid-derived suppressor cells (MDSCs) are expanded in cancer patients, have an intrinsic immunosuppressive function, and thus may play a role in resistance to immunotherapy. Ulceration of the melanoma primary is associated with more aggressive disease and is an independent prognostic factor for melanoma-specific survival. However, the underlying factors contributing to this more aggressive phenotype are not completely understood. The current study aims to correlate changes in circulating MDSC during immunotherapy in patients with ulcerated vs non-ulcerated melanoma primary tumors. Longitudinal changes in levels of circulating MDSCs were analyzed via flow cytometry in melanoma patients receiving immune checkpoint inhibitors (ICIs) and stratified by ulceration status. Following the initiation of therapy, the percentage of total MDSCs increased significantly in patients with both ulcerated (P = 0.003) and non-ulcerated (P < 0.001) tumors. When MDSCs were stratified by subset, the proportion of granulocytic MDSC (PMN-MDSC) decreased in patients with non-ulcerated tumors (P = 0.023), while the proportion remained stable in patients with ulcerated tumors (P = 0.121). The reduction in the proportion PMN-MDSC in non-ulcerated patients coincided with a statistically significant increase in the proportion of CD14+/CD15+ MDSC (P = 0.008), resulting in a greater proportion of CD14+/CD15+ MDSC in non-ulcerated patients as compared to ulcerated melanoma patients following two infusions of ICIs (27.3 ± 19.2% vs 16.1 ± 19.2%; P = 0.008). The trajectories of the MDSC populations described here provide insight into the altered tumor microenvironment in ulcerated melanoma and highlight key changes in a cell population that could contribute to immunotherapy resistance.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-01-28 DOI: 10.1097/CMR.0000000000001021

Lu Chen, Beichen Cai, Xuejun Ni, Qian Lin, Ruonan Ke, Xiaofen Wan, Tao Huang, Xiuying Shan, Biao Wang

{"title":"Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.","authors":"Lu Chen, Beichen Cai, Xuejun Ni, Qian Lin, Ruonan Ke, Xiaofen Wan, Tao Huang, Xiuying Shan, Biao Wang","doi":"10.1097/CMR.0000000000001021","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001021","url":null,"abstract":"Temozolomide is used in melanoma therapy, but the comparative efficacy and safety of monotherapy vs combination therapies are unclear. This meta-analysis evaluates temozolomide monotherapy vs combination therapies in melanoma patients. PubMed, Embase, and Cochrane Library were searched up to August 2024 for studies comparing temozolomide monotherapy with combination therapies in melanoma. Primary outcomes were 1-year survival and objective response rates (RR); secondary outcomes included hematologic and non-hematologic toxicities. Data were pooled using risk ratios with 95% confidence intervals (CIs). Seven studies were included. Combination therapies improved objective RR over temozolomide monotherapy (risk ratio 0.68, 95% CI: 0.53-0.88). One-year survival did not differ significantly between groups (risk ratio 0.81, 95% CI: 0.59-1.12). Temozolomide monotherapy was associated with reduced incidence of leukopenia (risk ratio 0.54, 95% CI: 0.30-0.95). Adding interferon-alpha (IFN-α) to temozolomide significantly improved 1-year survival (risk ratio 0.54, 95% CI: 0.35-0.84) and objective RR (risk ratio 0.57, 95% CI: 0.42-0.78) compared to temozolomide alone, without significantly increasing toxicity. Combination therapies enhance objective RR over temozolomide monotherapy, with similar 1-year survival. Temozolomide monotherapy offers a better hematologic safety profile. Combining temozolomide with IFN-α significantly improves survival and RR without increasing toxicity. Clinicians should balance efficacy and safety when choosing melanoma treatments.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SIAD onset in a patient affected by metastatic melanoma treated with immune checkpoint inhibitors: the role of nivolumab treatment. 接受免疫检查点抑制剂治疗的转移性黑色素瘤患者SIAD发病：纳武单抗治疗的作用

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-01-07 DOI: 10.1097/CMR.0000000000001017

Vincenzo Bassi, Valentina Apuzzi, Vito Vanella, Bianca Arianna Facchini, Olimpia Fattoruso

引用次数: 0

Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals. 可切除的III期黑色素瘤患者继发于辅助检查点抑制剂治疗的白癜风样色素沉着：来自两家三级医院的队列

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-01-07 DOI: 10.1097/CMR.0000000000001018

Mónica Pozuelo-Ruiz, Blanca de Unamuno-Bustos, Rodolfo D Palacios-Diaz, María Del Mar Blanes-Martínez, Gloria Juan-Carpena, Natividad Martínez-Banaclocha, Rafael Botella-Estrada

{"title":"Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals.","authors":"Mónica Pozuelo-Ruiz, Blanca de Unamuno-Bustos, Rodolfo D Palacios-Diaz, María Del Mar Blanes-Martínez, Gloria Juan-Carpena, Natividad Martínez-Banaclocha, Rafael Botella-Estrada","doi":"10.1097/CMR.0000000000001018","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001018","url":null,"abstract":"Vitiligo-like hypopigmentation induced by immune checkpoint inhibitors (ICIs) has been largely associated with improved survival outcomes in metastatic melanoma. However, its development during adjuvant ICI therapy and its role as a prognostic factor in this setting remain unclear. We aimed to describe ICI-induced vitiligo in a cohort of patients with resected stage III melanoma treated with adjuvant ICI and to identify differences in progression-free survival (PFS) and distant metastasis-free survival (DMFS) between those who developed vitiligo and those who did not. Patients and data were collected from two institutions, both retrospectively and prospectively, from January 2018 to February 2024. Patients were divided into 'vitiligo' and 'non-vitiligo' groups for comparisons. Of 40 patients, 22.5% developed ICI-induced vitiligo [median follow-up: 23 months (1-73)]. Treatments received were nivolumab (70%) and pembrolizumab (30%). Fifty-five percent of the patients completed 1 year of treatment, 37.5% discontinued and 7.5% were still ongoing. Vitiligo and non-vitiligo groups differed in the cause of treatment discontinuation (severe toxicity in vitiligo vs. progression in non-vitiligo, P = 0.005) and the occurrence of progression (none in vitiligo vs. 52% in non-vitiligo, P = 0.001). Survival analyses showed longer PFS in vitiligo group (P = 0.013) and no differences in DMFS (P = 0.111). ICI-induced vitiligo typically affected photo-exposed areas, with a median time to onset of 4 months (1-27). These preliminary results on ICI-induced vitiligo in adjuvant treatment are in agreement with those reported in advanced melanoma treatment, so its development in the adjuvant setting could be a sign of good prognosis as well.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature. pembrolizumab诱导的获得性脂肪营养不良：1例报告和文献回顾。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-20 DOI: 10.1097/CMR.0000000000000998

John Marsiglio, Jordan McPherson, Matthew Wahl, Siwen Hu-Lieskovan

{"title":"Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature.","authors":"John Marsiglio, Jordan McPherson, Matthew Wahl, Siwen Hu-Lieskovan","doi":"10.1097/CMR.0000000000000998","DOIUrl":"https://doi.org/10.1097/CMR.0000000000000998","url":null,"abstract":"Acquired generalized lipodystrophy (AGL) is a rare complication of immune checkpoint inhibitors (ICIs) and is associated with immune-mediated loss of adipose tissue, peripheral resistance to insulin, and serious metabolic complications. Here we report a new case of ICI-induced AGL and provide an updated literature review of published cases. We report a 39-year-old female patient treated with adjuvant pembrolizumab for stage IIIC nevoid melanoma with ICI-induced AGL. After six cycles of pembrolizumab, she developed a 40 lb weight loss with fat wasting, a decreased leptin level, significant liver function abnormalities, hepatic steatosis, hypertriglyceridemia, and subsequently was found to have severe insulin dependence and resistance. No corticosteroids were given and pembrolizumab was discontinued. AGL persists at 3-year follow up and patient remains free of melanoma progression. Literature review identified an additional seven patients who developed ICI-induced acquired lipodystrophy, predominantly female. Of the identified cases, three patients received steroids without resolution of their acquired lipodystrophy, while one patient had resolution without steroid treatment. Five patients and our case were treated with ICIs for melanoma, and all had at least a partial response to treatment. ICI-induced acquired lipodystrophy is an exceedingly rare event with profound clinical consequences. Our case report and literature review better characterized the clinical course and treatment outcomes of these patients. With the increasing utilization of ICIs in treating cancer, further studies to better understand the underlying mechanism and to guide clinical management of the metabolic complications are needed.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0